OCULAR MELANOMA

Information

  • Research Project
  • 2161042
  • ApplicationId
    2161042
  • Core Project Number
    U10EY006839
  • Full Project Number
    5U10EY006839-10
  • Serial Number
    6839
  • FOA Number
    RFA-EY-86-602
  • Sub Project Id
  • Project Start Date
    9/1/1986 - 39 years ago
  • Project End Date
    7/31/2000 - 25 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/1995 - 30 years ago
  • Budget End Date
    7/31/1996 - 29 years ago
  • Fiscal Year
    1995
  • Support Year
    10
  • Suffix
  • Award Notice Date
    7/26/1995 - 30 years ago
Organizations

OCULAR MELANOMA

The Collaborative Ocular Melanoma Study is a multicenter, randomized, controlled clinical trial designed to compare the efficacy of enucleation vs. irradiation in the treatment of eyes with choroidal melanoma. Candidates for the study will be newly diagnosed cases with choroidal melanoma in one eye greater than 3 mm in height and up to 18 mm by 8 mm in size and with no evidence of metastatic disease. Informed consent will be obtained from all patients prior to randomization. The outcome of primary interest is death from all causes. Secondary outcomes will include death from cancer, whether metastatic or not, diagnosis of other tumors, and preservation of vision. Complications of irradiation and changes in visual acuity will be documented and monitored carefully throughout follow-up. Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. The study will be conduced in cooperating clinics located throughout the United States. The study will be directed by an Executive Committee consisting of 12 to 15 study investigators and a Steering Committee to deal with day-to-day operational decisions. An independent Data and Safety Monitoring Committee will be responsible for assuring the ethical conduct of the study and for reviewing the accumulating data on a regular basis for evidence of adverse or beneficial effects of therapy.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    U10
  • Administering IC
    EY
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    VSN
  • Study Section Name
    Vision Research and Training Committee
  • Organization Name
    ONTARIO CANCER INSTITUTE
  • Organization Department
  • Organization DUNS
  • Organization City
    TORONTO
  • Organization State
  • Organization Country
    CANADA
  • Organization Zip Code
  • Organization District
    CANADA